Baclofen Forum vs Alkoholismus

Update in addiction medicine for the generalist

Addict Sci Clin Pract. 2013; 8(1): 6.
Published online 2013 March 13. doi: 10.1186/1940-0640-8-6

Johns Hopkins School of Medicine, Baltimore, MD, USA
2Montefiore Medical Center/Albert Einstein College of Medicine, Queens, NY, USA
3Yale University School of Medicine, New Haven, CT, USA
4Boston University School of Medicine, Boston, MA, USA
5University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA
Corresponding author.
Darius A Rastegar: drasteg1@jhmi.edu; Hillary V Kunins: hkunins@montefiore.org; Jeanette M Tetrault: jeanette.tetrault@yale.edu; Alexander Y Walley: awalley@bu.edu; Adam J Gordon: adam.gordon@va.gov

Im Text wird auch Baclofen erwähnt :
"A small, open-label study of the GABA agonist baclofen demonstrated reductions in drinks per drinking day and number of drinking days, as well as an increase in days abstinent, among people with alcohol dependence, despite a relatively high dropout rate due to side effects [The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface control65]. Additionally, baclofen has been evaluated as a potential treatment option for alcohol-dependent patients with cirrhosis given its lack of hepatotoxicity [The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface control66]. The authors of this study investigated the efficacy of baclofen compared with placebo for the treatment of alcohol dependence in patients with or without cirrhosis (N=80) [The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface control64]. Seventy-six percent of patients completed the 12-week study. The authors found no differences in percentage of heavy drinking days (roughly 26% in both groups), time to first drink, time to relapse to heavy drinking, or craving between the baclofen and placebo groups."

Komisch, dass kein Unterschied zur Placebo-Gruppe gefunden wurde...

LG, Werner

@Werner,

die Erklärung dürfte der Autor der Studie sein: Garbutt der Unsägliche ...
Erst wählt er Heavy Drinker als Probanden aus, die nach unseren Maßstäben allenfalls moderate Konsumenten wären und wundert sich dann, dass sie mit 30mg/d nicht abstinent werden.

Für diese Ministudie benötigte er dann 5 Jahre bis zur Veröffentlichung der Ergebnisse.
„No further word“, würde Jivaro sagen.

LG Federico